Pulmatrix (NASDAQ:PULM) Earns Media Sentiment Rating of 0.26
Headlines about Pulmatrix (NASDAQ:PULM) have trended positive on Tuesday, according to Accern. Accern identifies negative and positive news coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Pulmatrix earned a media sentiment score of 0.26 on Accern’s scale. Accern also assigned news headlines about the biotechnology company an impact score of 46.9598508063563 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Pulmatrix (NASDAQ PULM) opened at 1.65 on Tuesday. The company’s market cap is $33.20 million. The firm’s 50 day moving average is $2.19 and its 200-day moving average is $2.92. Pulmatrix has a 52 week low of $0.50 and a 52 week high of $6.98.
Pulmatrix (NASDAQ:PULM) last posted its quarterly earnings results on Friday, August 4th. The biotechnology company reported ($0.29) EPS for the quarter, beating the consensus estimate of ($0.30) by $0.01. Pulmatrix had a negative net margin of 3,328.91% and a negative return on equity of 152.56%. On average, analysts predict that Pulmatrix will post ($4.13) earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “Pulmatrix (NASDAQ:PULM) Earns Media Sentiment Rating of 0.26” was originally reported by Watch List News and is owned by of Watch List News. If you are reading this report on another domain, it was stolen and republished in violation of U.S. and international copyright & trademark law. The original version of this report can be accessed at https://www.watchlistnews.com/pulmatrix-nasdaqpulm-earns-media-sentiment-rating-of-0-26/1488398.html.
Pulmatrix Company Profile
Pulmatrix, Inc is a clinical stage biopharmaceutical company developing inhaled therapies to address serious pulmonary disease. The Company’s product pipeline is focused on advancing treatments for rare diseases, including PUR1900, an inhaled anti-fungal for patients with lung disease, including cystic fibrosis.
Receive News & Ratings for Pulmatrix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.